Skip to main content

Gene Delivery Systems

Revvity Gene Delivery, where SIRION Biotech’s expertise lives on, supports your cell and gene therapy development process, offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production.

Whether you need small scale viral production or full scale viral vector optimization and manufacture, Revvity Gene Delivery has you covered.

Revvity Gene Delivery supports you through every phase of cell and gene therapy development.

gene-delivery-viral-overview_712w.jpg

The  revvity gene delivery advantage

With clients in Cancer Research, Neurosciences, Regenerative Medicines, Gene Therapy, CAR-T Cell Development & Vaccine Development, we understand the technical challenges of viral vector engineering and manufacturing, no matter what your application.

  • More than 15 years of viral vector development and production experience
  • Flexible production scales up to 50 Liters
  • Extensive range of customizable QC options
  • CDMO network for smooth transfer of processes to GMP manufacturing  
  • Comprehensive consultation and project management by viral vector experts 
Research and discovery:
  • Therapeutic payload identification (e.g. microRNA sequences)
  • Novel AAV capsid engineering (e.g.AAV Evolution)
  • Nanobody targeting 
  • Therapeutic payload identification (e.g. microRNA sequences)
  • Novel AAV capsid engineering (e.g.AAV Evolution)
  • Nanobody targeting 
Viral vector development:
  • Optimized Viral Vector Backbones
  • Therapeutic payload cassette optimization
  • Lentivirus surface modification technology 
  • Optimized Viral Vector Backbones
  • Therapeutic payload cassette optimization
  • Lentivirus surface modification technology 
Preclinical manufacture:
  • Upstream and downstream process development (non-GMP)
  • Up to 50L AAV manufacturing capacity
  • PoC and biodistribution studies of lead candidate batches with a CRO network 
  • Upstream and downstream process development (non-GMP)
  • Up to 50L AAV manufacturing capacity
  • PoC and biodistribution studies of lead candidate batches with a CRO network 
GMP alliances

Moving projects from the preclinical phase to a GMP manufacturing facility can require set up of entirely new processes and analytics. During the early R&D and preclinical project stages at Revvity Gene Delivery, relevant individual project aspects are considered from the start to ensure a seamless clinical project transfer.  

Revvity Gene Delivery has developed a global CDMO network over the last 5 years and can recommend and introduce CDMOs worldwide that best suit customer location and individual project requirements.

Revvity Gene Delivery services accelerate the preclinical phase while developing appropriate upstream and downstream processes and analytic tools to enable a smooth Project Transfer – speeding up the project transfer and process development phase at a CDMO by up to 8 months. 

Moving projects from the preclinical phase to a GMP manufacturing facility can require set up of entirely new processes and analytics. During the early R&D and preclinical project stages at Revvity Gene Delivery, relevant individual project aspects are considered from the start to ensure a seamless clinical project transfer.  

Revvity Gene Delivery has developed a global CDMO network over the last 5 years and can recommend and introduce CDMOs worldwide that best suit customer location and individual project requirements.

Revvity Gene Delivery services accelerate the preclinical phase while developing appropriate upstream and downstream processes and analytic tools to enable a smooth Project Transfer – speeding up the project transfer and process development phase at a CDMO by up to 8 months. 

Questions?
We’re here to help.

Contact us

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.